GSK (NYSE:GSK) Stock Rating Lowered by StockNews.com

GSK (NYSE:GSK) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report released on Sunday.

A number of other research analysts have also recently issued reports on GSK. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and cut their price target for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Seven equities research analysts have rated the stock with a hold rating, one has issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Trading Up 1.4 %

GSK stock opened at $33.93 on Friday. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The stock has a market capitalization of $70.32 billion, a price-to-earnings ratio of 22.03, a P/E/G ratio of 1.52 and a beta of 0.63. The business has a fifty day moving average price of $34.67 and a 200 day moving average price of $38.35. GSK has a fifty-two week low of $32.83 and a fifty-two week high of $45.92.

Institutional Trading of GSK

A number of institutional investors have recently bought and sold shares of the business. Eastern Bank bought a new position in shares of GSK in the 3rd quarter worth $26,000. Sunbelt Securities Inc. boosted its holdings in GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 302 shares during the last quarter. Concord Wealth Partners boosted its holdings in GSK by 231.8% during the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after buying an additional 547 shares during the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in shares of GSK in the 2nd quarter valued at about $37,000. Finally, Fortitude Family Office LLC acquired a new stake in shares of GSK in the 3rd quarter valued at approximately $42,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.